Sector News

Lilly moves forward with biologics plant expansion that will add 130 jobs

May 9, 2017
Life sciences

The on-again, off-again $215 million expansion of an Eli Lilly biologics plant in Ireland is on again.

The Indianapolis, Indiana-based company said Monday it will move forward with plans to add a manufacturing line at its site in Kindsdale, County Cork. It said construction should begin in coming months and commissioning will begin in 2019. The expansion is expected to add about 130 workers to the site by 2020.

Spokesperson Tamara Ann Hull said in an email that because negotiations are underway, specifics of the investment were not being released. Earlier reports put the cost at about €200 million.

Tremors of concern spread through Ireland in February when Lilly said it halted preparations for the project. That ignited speculation among some politicians that Lilly might divert funds to the U.S. after President Trump held a meeting with pharma execs in which he urged them to invest in U.S. manufacturing. Lilly’s new CEO David Ricks was at that meeting.

Weeks later, Ricks announced an $85 million expansion at an insulin device plant in Indianapolis and pointed to $850 million in capital outlays this year in the U.S. as an indicator of its commitment to investing there.

Lilly has been expanding its biopharma operations in Cork for some years. In 2012, it began construction of a 22,000-square-meter bioprocessing plant. It also has a 158,000-square-meter monoclonal antibody plant there that was completed in 2010.

The site also does API production for a host of small molecule drugs. Last year, the company said it would invest nearly $40 million (€35 million) to build a continuous manufacturing facility there. At the time it said it had invested about $740 million (€650 million) in the site in 8 years, hiring 350 employees.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach